Revolution Medicines, Inc. (RVMDW)

NASDAQ: RVMDW · Real-Time Price · USD · Warrants
0.109
+0.029 (36.38%)
Mar 12, 2025, 4:00 PM EST - Market closed
36.38%
Market Cap 7.29B
Revenue (ttm) n/a
Net Income (ttm) -600.09M
Shares Out 185.91M
EPS (ttm) -3.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 734
Open 0.100
Previous Close 0.080
Day's Range 0.100 - 0.109
52-Week Range 0.100 - 0.109
Beta 1.46
Analysts n/a
Price Target n/a
Earnings Date Feb 26, 2025

About RVMDW

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clin... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 534
Stock Exchange NASDAQ
Ticker Symbol RVMDW
Full Company Profile

Financial Performance

News

There is no news available yet.